Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma

Cancer

Volumn 79, Issue 7, 1997, Pages 1343-1350

  Berg, John ^a   Gebhardt, Mark C ^b   Rand, William M ^c  

^a TUFTS UNIVERSITY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

animal models; canine; chemotherapy; metastases; osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN;

ADOLESCENT; ANIMAL MODEL; ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MALE; METASTASIS; NONHUMAN; OSTEOSARCOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL;

EID: 0030945005     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19970401)79:7<1343::aid-cncr11>3.0.co;2-#     Document Type: Article

References (31)

1. Nissen-Meyer R, Host H, Kjellgren K, Mansson B, Norin T. Short perioperative versus long-term adjuvant chemotherapy. Recent Res Cancer Res 1985;98:91-8.
2. Ludwig Breast Cancer Study Group. Combination adjuvant chemotherapy for node-positive breast cancer: inadequacy of a single perioperative cycle. N Engl J Med 1988;319:677-83.
3. Ludwig Breast Cancer Study Group. Prolonged disease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N Engl J Med 1989;320:491-6.
4. Sertoli M, Pronzato P, Rubagotti A, Queirolo P, Catturich A, Canavese G, et al. A randomized study of perioperative chemotherapy in primary breast cancer. In: Salmon SE (editor). Adjuvant therapy of cancer. Philadelphia: W.B. Saunders, 1990:196-203.
5. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-33.
6. DeWys WD. Studies correlating the growth rate of a tumor and its metastases and providing evidence for tumor-related systemic growth-retarding factors. Cancer Res 1972;32:374-9.
7. Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976;60:1749-60.
8. Gunduz N, Fisher B, Saffer EA. Effect of surgical removal on the growth and kinetics of residual tumor. Cancer Res 1979;39:3861-5.
9. Fisher B, Gunduz N, Saffer EA. Interrelation between tumor cell proliferation and 17-fluoresceinated estrone binding following primary tumor removal, radiation, cyclophosphamide, or tamoxifen. Cancer Res 1983;43:5244-7.
10. Gebhardt MC, Cheng EY, Roth YF, Litwak GJ, Taira K, Suit HD, et al. Accelerated growth of a secondary tumor focus after surgical resection of a primary murine osteosarcoma. Cell Tissue Kinetics 1988;21:60.
11. Fisher B, Gunduz N, Saffer EA. Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases. Cancer Res 1983;43:1488-92.
12. Bell RS, Roth YF, Gebhardt MC, Bell DF, Rosenberg AE, Mankin HJ, et al. Timing of chemotherapy and surgery in a murine osteosarcoma model. Cancer Res 1988;48:5538-8.
13. O'Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-28.
14. Chen C, Parangi S, Tolentino MJ, Folkman J. A strategy to discover circulating angiogenesis inhibitors generated by human tumors. Cancer Res 1995;55:4230-3.
15. Brodey RS. The use of naturally occurring cancer in domestic animals for research into human cancer: general considerations and a review of canine skeletal osteosarcoma. Yale J Biol Med 1979;52:345-61.
16. Brodey RS, Abt DA. Results of surgical treatment in 65 dogs with osteosarcoma. J Am Vet Med Assoc 1976;168:1032-5.
17. Spodnick GJ, Berg J, Rand WM, Schelling SH, Cuoto G, Harvey HJ, et al. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 1992;200:995-9.
18. Shapiro W, Possum TW, Kitchell BE, Couto CG, Theilen GH. Use of cisplatin for treatment of appendicular osteosarcoma in dogs. J Am Vet Med Assoc 1988;192:507-11.
19. Kraegel SA, Madewell BR, Simonson E, Gregory CR. Osteogenic sarcoma and cisplatin chemotherapy in dogs: 16 cases (1986-1989). J Am Vet Med Assoc 1991;199:1057-9.
20. Straw RC, Withrow SJ, Richter SL, Powers BE, Klein MK, Postorino NC, et al. Amputation and cisplatin for treatment of canine osteosarcoma. J Vet Int Med 1991;5:205-10.
21. Thompson JP, Fugent MJ. Evaluation of survival times after limb amputation, with and without subsequent administration of cisplatin, for treatment of appendicular osteosarcoma in dogs: 30 cases (1979-1990). J Am Vet Med Assoc 1992;200:531-3.
22. Berg J, Weinstein MJ, Schelling SH, Rand WM. Treatment of dogs with osteosarcoma by administration of cisplatin after amputation or limb-sparing surgery: 22 cases (1987-1990). J Am Vet Med Assoc 1992;200:2005-8.
23. Berg J, Weinstein MJ, Springfield DS, Rand WM. Results of surgery and doxorubicin chemotherapy in dogs with osteosarcoma. J Am Vet Med Assoc 1995;206:1555-60.
24. Mauldin GN, Matus RE, Withrow SJ, Patnaik AK. Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. J Vet Int Med 1988;2:177-80.
25. Forrest LJ, Dodge RK, Page RL, Heidner GL, McEntee MC, Novotney CA, et al. Relationship between quantitative tumor scintigraphy and time to metastasis in dogs with osteosarcoma. J Nucl Med 1992;33:1542-7.
26. Ogilvie GK, Krawiec DR, Gelberg HB, Twardock AR, Reschke RW, Richardson BC. Evaluation of a short-term diuresis protocol for the administration of cisplatin. Am J Vet Res 1988;49:1076-8.
27. Malawer MM, Link MP, Donaldson SS. Sarcomas of bone. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 4th edition. Philadelphia: J.B. Lippincott Co., 1993:1509-66.
28. Cooper MR, Cooper MR. Principles of medical oncology. In: Holleb AI, Fink DI, Murphy GP, editors. American Cancer Society textbook of clinical oncology. Atlanta: American Cancer Society, 1991:47-68.
29. Goorin A, Baker A, Gleser P, Ayala A, Gebhardt M, Harris M, et al. No evidence for improved event free survival with presurgical chemotherapy for non-metastatic extremity osteogenic sarcoma: preliminary results of randomized pediatric Oncology Group trial 8651. Proc Am Soc Clin Oncol 1995;14:444.
30. Goldstein H, McNeil BJ, Zufall E, Jaffe N, Treves S. Changing indications for bone scintigraphy in patients with osteosarcoma. Radiology 1980;135:177-80.
31. Jaffe N, Smith E, Abelson H, Frei E. Osteogenic sarcoma: alterations in the pattern of pulmonary metastases with adjuvant chemotherapy. J Clin Oncol 1983;1:251-4.